For the quarter ended September 2024, Supernus Pharmaceuticals (SUPN ... year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations ...

Supernus Pharmaceuticals' FDA approval for ONAPGO in Parkinson's Disease offers optimism despite past challenges, with a ...

As such, the Zacks rating upgrade for Supernus is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price. The change in a company's future ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Pfizer (PFE – Research Report) and Supernus ...

Short interest in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) decreased during the last reporting period, falling from 6.64M to 6.20M. This put 17.19% of the company's publicly available shares short.

The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail). We're pleased to report that Supernus Pharmaceuticals shareholders have ...

Earnings, adjusted for one-time gains ... A live webcast with presentation sl Supernus Pharmaceuticals Inc (SUPN) reports a 32% revenue increase, driven by Qelbree and Gocovri, while advancing ...

View Supernus Pharmaceuticals, Inc. (SUPN) current and estimated P/E ratio data provided by Seeking Alpha.